Pro Medicus: $43m US contract boosts outlook

The Pro Medicus Ltd (ASX: PME) share price is in focus after the company secured a major 7-year, A$43 million contract with Virtua Health in the United States. This deal will see PME’s cloud-based Visage 7 enterprise imaging platform rolled out across Virtua’s health system.

What did Pro Medicus report?

• Signed a 7-year contract worth A$43 million with Virtua Health, based in New Jersey, USA
• The agreement covers the unified Visage 7 Viewer, Workflow, Open Archive, and Cardiology products
• Contract to be delivered via PME’s cloud-based platform, supporting hospital-wide image access and EHR integration
• Revenue tied to a transaction-based model, allowing for potential upside
• Implementation to begin immediately, with full rollout targeted for late Q2/early Q3 2027

What else do investors need to know?

Virtua Health is a major healthcare provider in South Jersey with five hospitals and 15,000 employees. This win adds to Pro Medicus’ growing footprint among large US health systems choosing fully cloud-based imaging.

The deal further validates PME’s CloudPACS strategy, which aims to set industry standards in North American healthcare IT. The contract includes Visage’s new cardiology offering, indicating rising demand for ‘full stack’ unified imaging solutions in major health networks.

What did Pro Medicus management say?

Pro Medicus CEO Dr Sam Hupert said:

Virtua provides outstanding, innovative care to all of South Jersey. They join an ever growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

What’s next for Pro Medicus?

Pro Medicus management reports a strong pipeline across all market segments, with increasing global interest in the company’s end-to-end imaging solutions. The Virtua deal is expected to further entrench PME in the US market and demonstrates traction for their ‘full stack’ strategy including additional specialities like cardiology.

Planning for the Virtua rollout commences immediately, with the system set to go live from late 2027. PME continues to focus on winning large, long-term contracts with major healthcare providers worldwide.

Pro Medicus share price snapshot

Over the 12 months, Pro Medicus shares have declined 38%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post Pro Medicus: $43m US contract boosts outlook appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Deep Yellow, PLS, Pro Medicus shares
• 5 things to watch on the ASX 200 on Wednesday
• Should I buy Pro Medicus shares after its big news?
• Pro Medicus signs A$24M US deal
• ASX 200 utilities and healthcare shares win the week again

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.